Cytek Biosciences, Inc. (CTKB)

Market Cap	581.05M +11.7%
Revenue (ttm)	201.49M +0.5%
Net Income	-66.54M
EPS	-0.52
Shares Out	128.55M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	428,169
Open	4.510
Previous Close	4.530
Day's Range	4.500 - 4.638
52-Week Range	2.370 - 6.180
Beta	1.28
Analysts	Hold
Price Target	5.63 (+24.56%)
Earnings Date	May 7, 2026

About CTKB

Cytek Biosciences, Inc., a cell analysis solutions company, provides cell analysis tools that facilitate scientific advances in biomedical research and clinical applications. The company offers Cytek aurora, northern lights systems, and Cytek aurora evo systems delivers cell analysis; Cytek Aurora CS System, a cellular complexity to perform additional downstream genomic and proteomic studies using phenotyping approaches; enhanced small particle detection; Cytek amnis imagestream imaging flow cytometers; Cytek guava muse cell analyzers; Cytek mu...

• Industry: Medical Devices
• Sector: Healthcare
• IPO Date: Jul 23, 2021
• Employees: 702
• Stock Exchange: NASDAQ
• Ticker Symbol: CTKB
• Website: https://cytekbio.com

Financial Performance

In 2025, Cytek Biosciences's revenue was $201.49 million, an increase of 0.52% compared to the previous year's $200.45 million. Losses were -$66.54 million, 1005.3% more than in 2024.

Analyst Summary

According to 4 analysts, the average rating for CTKB stock is "Hold." The 12-month stock price target is $5.63, which is an increase of 24.56% from the latest price.

Price Target

$5.63

(24.56% upside)

Analyst Consensus: Hold